Cenya Imaging BV is addressing the need to measure the biodistribution of cell therapies in humans and other species by developing Cenya BEACONs, an imaging agent. BEACONs can passively label a wide range of cell types (eg dendritic cells, T cells, stem cells etc), without impairing their function, enabling the cells to be tracked and quantified in vivo at multiple timepoints over extended timelines using MRI. BEACONs can be manufactured to GMP grade, and have been approved for use in a clinical trial with dendritic cells; several additional clinical trials with different cell types are being prepared.